{"text": ["Pfizer", "(PFE)", "Stock", "Sinks", "As", "Market", "Gains:", "What", "You", "Should", "Know"], "created_at": "2019-09-30 21:45:09"}
{"text": ["Mylan", "(MYL)", "to", "Pay", "$30M", "to", "Settle", "SEC", "Charges", "for", "EpiPen"], "created_at": "2019-09-30 21:45:09"}
{"text": ["Pfizer,", "Walgreens,", "UnitedHealth,", "Dow,", "3M", "Are", "5", "Worst", "Dow", "Jones", "Stocks", "This", "Year"], "created_at": "2019-09-30 20:25:55"}
{"text": ["Pfizer's", "JAK1", "Inhibitor", "Meets", "All", "Goals", "in", "2nd", "Phase", "III", "Study"], "created_at": "2019-09-30 14:46:02"}
{"text": ["Company", "News", "For", "Sep", "30,", "2019"], "created_at": "2019-09-30 13:30:01"}
{"text": ["California", "investor", "buys", "67,000-square-foot", "facility", "in", "Durham"], "created_at": "2019-09-30 11:58:22"}
{"text": ["Pfizer", "Presents", "Interim", "Analysis", "Results", "from", "Phase", "3", "BEACON", "CRC", "Trial", "of", "BRAFTOVI\u00ae", "(Encorafenib),", "MEKTOVI\u00ae", "(Binimetinib)", "and", "Cetuximab", "for", "the", "Treatment", "of", "BRAFV600E-Mutant", "Metastatic", "Colorectal", "Cancer"], "created_at": "2019-09-30 06:30:00"}
